FXTM information and reviews
FXTM
93%
IronFX information and reviews
IronFX
92%
Libertex information and reviews
Libertex
91%
FXCC information and reviews
FXCC
90%
Markets.com information and reviews
Markets.com
89%
FxPro information and reviews
FxPro
88%
EUR/USD
1.1729
BTC/USD
43 862.55
GBP/USD
1.3655
USD/JPY
109.4070
USD/CHF
0.9272
USD/CAD
1.2836
EUR/JPY
128.3269

Coronavirus second wave spells opportunity as well as uncertainty


27 October 2020

After a summer of fun, celebration and relaxation, many of us came away with a renewed sense of appreciation for all of life’s little pleasures that seemed so distant just a few months prior. Spending time with friends and family, walks in the park and restaurant meals took on new-found significance in the post-lockdown era. But as the number of new coronavirus cases soars worldwide and restrictions are reintroduced in various countries, people are beginning to brace themselves for a return to the dark times of spring.

Vaccine race to bring bulls out of hiding


We all remember how devastating social distancing was for the global economy, with the world’s indices losing an average of between 30-40% in a matter of days. However, several sectors managed to buck the trend. Some of the most notable among these were pharmaceuticals and biotech. With the race for a coronavirus vaccine hotting up again just now, we would be wise to expect to see some movement in these segments once more. While there was a lot more uncertainty about which companies would be in the running to get their vaccine to market first back in March and April, the list of potential candidates is now much shorter. That makes it significantly easier to pick which horse(s) to back.

While there are currently 42 vaccines in clinical trials, only 10 of them are in the final stage of testing known as “Phase 3”. The most promising of these are thought to be US biotech firm Moderna’s candidate, a US-German joint effort between BioNTech and Pfizer and a European project headed up by the University of Oxford and AstraZeneca.

Naturally, this has been very good not only for the reputations of the companies involved but for their valuations, too. Luckily for us, all of these organisations (bar the University of Oxford, of course) are publicly traded companies. That means that any progress and success in the COVID vaccine race will most likely translate to a rise in the relevant companies’ share prices.

Only fools rush in


With things as they are, you might be forgiven for thinking otherwise, but there really is more to life — and the pharmaceutical market — than the novel coronavirus. That’s why it’s important not only to look at a given firm’s position in the vaccine race but also at its broader business prospects. Does it have any other promising drugs in the pipeline? How many patents does it currently own? What did its EBITDA look like before 2020? Pfizer, for instance, has close to 30 varied programmes in late-stage testing or awaiting regulatory approval, including a promising pneumococcal vaccine and its chronic pain drug tanezumab. AstraZeneca, on the other hand, is very much all-in on cancer immunotherapy at the moment, with nearly all of its 14 current Phase 3 drugs being designated as oncotherapeutics. The key message here is: Do your due diligence before opening a position.

Trade Big Pharma with Libertex


The good news is, wherever you think the biotech and pharmaceutical markets are going, Libertex can help. Because Libertex offers both long and short positions, you can trade whether your chosen instruments go up or down. What’s more, we offer CFD trading in both of the frontrunners in the vaccine race, Pfizer and Moderna, so you can either pick a side or just as easily hedge your bets by backing both. Create your own Libertex account today if you haven’t already got one and start trading the markets’ hottest instruments on the premier financial platform!

#source

Related

US Markets lost major support, Asian Indices are melting
US Markets lost major support, Asian Indices are melting

Global markets closed last week on the back foot, and no significant positive factors emerged in Asian trading, increasing the flight to safety. The Hang Seng lost...

20 Sep 2021

US Retail sales and other data has supported Dollar
US Retail sales and other data has supported Dollar

The US Retail sales notably exceeded expectations, adding 0.7% in August vs an expected 0.7% decline. The increase to August last year is an impressive 14.9%...

17 Sep 2021

Geopolitics Fire Up Up and Cryptos Are Booming
Geopolitics Fire Up Up and Cryptos Are Booming

Futures in the United States and Europe are trading lower today as investors are worried about the new security agreement between the U.S., the U.K. and Australia...

16 Sep 2021

UK inflation surges, stocks struggle
UK inflation surges, stocks struggle

European markets flat at the open this morning as UK inflation surged to a record high in August and Chinese economic data was soft. China’s retail sales fell to...

15 Sep 2021

Gold is anxiously waiting for the US inflation data
Gold is anxiously waiting for the US inflation data

Gold, hovering around $1790 since last Thursday, might take an even harder hit. The bears are waiting for a good signal to launch an attack. It is now holding it below significant levels...

14 Sep 2021

Here Is Why Stock Futures Are Trading Lower
Here Is Why Stock Futures Are Trading Lower

Despite a week of doom and gloom in the stock markets, futures in the United States are still trading lower. Since February, the S&P 500 has been on its longest...

13 Sep 2021


Editors' Picks

OctaFX information and reviews
OctaFX
86%
HotForex information and reviews
HotForex
85%
XM information and reviews
XM
80%
FXCM information and reviews
FXCM
79%
Vantage FX information and reviews
Vantage FX
78%
Moneta Markets information and reviews
Moneta Markets
77%

© 2006-2021 Forex-Ratings.com

The usage of this website constitutes acceptance of the following legal information.
Any contracts of financial instruments offered to conclude bear high risks and may result in the full loss of the deposited funds. Prior to making transactions one should get acquainted with the risks to which they relate. All the information featured on the website (reviews, brokers' news, comments, analysis, quotes, forecasts or other information materials provided by Forex Ratings, as well as information provided by the partners), including graphical information about the forex companies, brokers and dealing desks, is intended solely for informational purposes, is not a means of advertising them, and doesn't imply direct instructions for investing. Forex Ratings shall not be liable for any loss, including unlimited loss of funds, which may arise directly or indirectly from the usage of this information. The editorial staff of the website does not bear any responsibility whatsoever for the content of the comments or reviews made by the site users about the forex companies. The entire responsibility for the contents rests with the commentators. Reprint of the materials is available only with the permission of the editorial staff.
We use cookies to improve your experience and to make your stay with us more comfortable. By using Forex-Ratings.com website you agree to the cookies policy.